Cargando…
IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998229/ https://www.ncbi.nlm.nih.gov/pubmed/32013927 http://dx.doi.org/10.1186/s12885-020-6587-z |
_version_ | 1783493818827407360 |
---|---|
author | Chen, Feier Qu, Meng Zhang, Feng Tan, Zhenyu Xia, Qinghua Hambly, Brett D. Bao, Shisan Tao, Kun |
author_facet | Chen, Feier Qu, Meng Zhang, Feng Tan, Zhenyu Xia, Qinghua Hambly, Brett D. Bao, Shisan Tao, Kun |
author_sort | Chen, Feier |
collection | PubMed |
description | BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues. RESULTS: A significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α(high) and IL-36α(low) (P = 0.003) or IL-36γ(high) and IL-36γ(low) (P = 0.03). Survival curves varied significantly when further stratification into sub-groups, on the basis of combined levels of expression of two isotypes of IL-36 was undertaken. A significant difference was observed when levels of IL-36α and IL-36β were combined (P = 0.01), or a combination of IL-36α plus IL-36γ (P = 0.002). The sub-groups with a combination of IL-36α(high) plus IL-36β(high), or IL-36α(high) plus IL-36γ(low) exhibited the longest survival time among CRC patients. In contrast, the sub-groups of IL-36α(low) plus IL-36β(high) or IL-36α(low) plus IL-36γ(high) had the shortest overall survival. Using the log-rank test, IL-36α(high) expression significantly improved survival in patients with an invasion depth of T4 (P < 0.0001), lymph node metastasis (P = 0.04), TNM III-IV (P = 0.03) or with a right-sided colon tumour (P = 0.02). Similarly, IL-36γ(low) expression was significantly associated with improved survival in patients with no lymph node metastasis (P = 0.008), TNM I-II (P = 0.03) or with a left-sided colon tumour (P = 0.05). Multivariate analysis demonstrated that among IL-36α, IL-36β and IL-36γ, only IL-36α (HR, 0.37; 95% CI, 0.16–0.87; P = 0.02) was an independent factor in survival, using Cox proportional hazards regression analysis. CONCLUSION: IL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC. |
format | Online Article Text |
id | pubmed-6998229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69982292020-02-05 IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? Chen, Feier Qu, Meng Zhang, Feng Tan, Zhenyu Xia, Qinghua Hambly, Brett D. Bao, Shisan Tao, Kun BMC Cancer Research Article BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues. RESULTS: A significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α(high) and IL-36α(low) (P = 0.003) or IL-36γ(high) and IL-36γ(low) (P = 0.03). Survival curves varied significantly when further stratification into sub-groups, on the basis of combined levels of expression of two isotypes of IL-36 was undertaken. A significant difference was observed when levels of IL-36α and IL-36β were combined (P = 0.01), or a combination of IL-36α plus IL-36γ (P = 0.002). The sub-groups with a combination of IL-36α(high) plus IL-36β(high), or IL-36α(high) plus IL-36γ(low) exhibited the longest survival time among CRC patients. In contrast, the sub-groups of IL-36α(low) plus IL-36β(high) or IL-36α(low) plus IL-36γ(high) had the shortest overall survival. Using the log-rank test, IL-36α(high) expression significantly improved survival in patients with an invasion depth of T4 (P < 0.0001), lymph node metastasis (P = 0.04), TNM III-IV (P = 0.03) or with a right-sided colon tumour (P = 0.02). Similarly, IL-36γ(low) expression was significantly associated with improved survival in patients with no lymph node metastasis (P = 0.008), TNM I-II (P = 0.03) or with a left-sided colon tumour (P = 0.05). Multivariate analysis demonstrated that among IL-36α, IL-36β and IL-36γ, only IL-36α (HR, 0.37; 95% CI, 0.16–0.87; P = 0.02) was an independent factor in survival, using Cox proportional hazards regression analysis. CONCLUSION: IL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC. BioMed Central 2020-02-03 /pmc/articles/PMC6998229/ /pubmed/32013927 http://dx.doi.org/10.1186/s12885-020-6587-z Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Chen, Feier Qu, Meng Zhang, Feng Tan, Zhenyu Xia, Qinghua Hambly, Brett D. Bao, Shisan Tao, Kun IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title | IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title_full | IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title_fullStr | IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title_full_unstemmed | IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title_short | IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
title_sort | il-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998229/ https://www.ncbi.nlm.nih.gov/pubmed/32013927 http://dx.doi.org/10.1186/s12885-020-6587-z |
work_keys_str_mv | AT chenfeier il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT qumeng il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT zhangfeng il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT tanzhenyu il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT xiaqinghua il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT hamblybrettd il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT baoshisan il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer AT taokun il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer |